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2

Chronic joint pain (CJP) is among the signiﬁcant musculoskeletal
comorbidities in sickle cell disease (SCD) individuals. However, many
healthcare professionals have difficulties in understanding and evaluating it. In
addition, most musculoskeletal evaluation procedures do not consider central
nervous system (CNS) plasticity associated with CJP, which is frequently
maladaptive. This review study highlights the potential mechanisms of CNS
maladaptive plasticity related to CJP in SCD and proposes reliable instruments
and methods for musculoskeletal assessment adapted to those patients.
A review was carried out in the PubMed and SciELO databases, searching
for information that could help in the understanding of the mechanisms
of CNS maladaptive plasticity related to pain in SCD and that presented
assessment instruments/methods that could be used in the clinical setting by
healthcare professionals who manage chronic pain in SCD individuals. Some
maladaptive CNS plasticity mechanisms seem important in CJP, including the
impairment of pain endogenous control systems, central sensitization, motor
cortex reorganization, motor control modiﬁcation, and arthrogenic muscle
inhibition. Understanding the link between maladaptive CNS plasticity and CJP
mechanisms and its assessment through accurate instruments and methods
may help healthcare professionals to increase the quality of treatment offered
to SCD patients.
KEYWORDS

musculoskeletal pain, symptoms assessment, red cell disorders, practical reasoning,
evidence-based medicine
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Introduction

Method

Sickle cell disease (SCD) is a set of hereditary diseases
caused by substituting glutamine acid for valine at the
sixth position of the hemoglobin β chains, which leads
to the presence of hemoglobin S (HbS). Conditions such
as low oxygen concentration, hypovolemia, and others can
precipitate the structure twisting of HbS molecules fibers
forming the sickle-shaped red blood cell membrane causing
vaso-occlusive crises, which are the main reason for pain
complaints in this population throughout life (1). The pain
in SCD individuals can be acute or chronic and can emerge
from nociceptive, inflammatory, and neuropathic mechanisms
(2). SCD pain syndromes are classified as intermittent,
persistent pain between vaso-occlusive crises and chronic pain
complications (3).
Among the chronic pain complications, chronic joint pain
(CJP) is a common condition in SCD that may also be associated
with several musculoskeletal problems such as osteomyelitis,
dactylitis, arthritis, and osteonecrosis both in adult and pediatric
individuals (4–6). These chronic pain complications have a
higher incidence in SCD and play an additional role in chronic
pain generation (4, 5). The CJP may be focal when involving a
single joint or multifocal when involving more than one joint
(7). However, to date, few studies demonstrate the influence
of maladaptive plasticity in the central nervous system (CNS)
in the maintenance of CJP in SCD individuals, although these
individuals have chronic pain with nociceptive, neuropathic, and
possible nociplastic pain characteristics (8, 9). The presence of
central sensitization, for example, is related to more episodes
of pain crisis and frequent hospitalizations (10). Of utmost
importance, few studies were developed explicitly for CJP
in SCD.
The poor correlation between structural lesions, the
intensity of self-reported pain (11), and the diffuse nature of the
symptoms make CJP assessment a challenge for clinicians and
healthcare professionals. In general, healthcare professionals
have poor knowledge about pain neuroscience mechanisms
(12) and reliable ways of assessing it (13, 14). This poor
knowledge goes against the International Association Study of
Pain (IASP) recommendation in the declaration of the Montreal
meeting, which highlights that all people with pain have the
right to have access to appropriate assessment and treatment
of the pain by adequately trained healthcare professionals
(15). Thus, considering the potential relation between CJP
and central maladaptive plasticity in SCD individuals and
the deficit in healthcare professionals’ knowledge about pain
neuroscience mechanisms and pain assessment, this review
aims to highlight the mechanisms of CNS maladaptive
plasticity that might be related to CJP in SCD and propose
a battery for reliable musculoskeletal assessment adapted to
those patients.

This review was carried out in the PubMed and SciELO
databases, searching for information that could help in
the understanding of the mechanisms of CNS maladaptive
plasticity related to pain in SCD and that presented assessment
instruments/methods that could be used in the clinical setting
by healthcare professionals who manage chronic pain in SCD
individuals. There was no limit placed on the publication year,
and the searching was carried out through a combination of
keywords such as Sickle Cell Disease and Joint Pain or Chronic
Pain or Pain Assessment or Central Sensitization Evaluation or
Painful Movement Assessment, Chronic Joint Pain and Cortical
Reorganization or Arthrogenic Muscle Inhibition or Chronic
Inventory Central Sensitization or Quantitative Sensory Test or
Clinical Evaluation. In addition, the reference list of papers also
was searched.
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Chronic joint pain in SCD: An
overview of the problem
International Association Study of Pain defines pain as “An
unpleasant sensory and emotional experience, associated with,
or resembling that associated with, actual or tissue damage” (16).
Pain plays a vital role in the organism’s defense reaction to a
hostile environment, and evidence of this is that in individuals
with pain insensitivity, injuries are not perceived as such,
decreasing life expectancy (17). On the other hand, chronic
pain is persistent beyond 3–6 months, has no functional role,
and is responsible for rendering dysfunctional several biological
systems (18). In SCD, the constant joint tissue injuries secondary
to the vaso-occlusive crisis are critical in developing chronic
joint pain.
Primary afferent nociceptors richly innervate the joint in
their capsule and synovium (19). These fibers are mostly
from types Aδ and C and can be classified into two types:
(a) True nociceptors; (b) Silent nociceptors. True nociceptors
respond to mechanical nociceptive stimuli even in nonpathological conditions. As for the silent nociceptors, to respond
to this type of stimuli, they must be primarily sensitized
by inflammation-inducing aggressors (19, 20). The primary
afferent nociceptors have on their membranes a wide variety
of transient receptor potential ion channels that are responsible
for the transduction of a wide variety of noxious stimuli arising
from high magnitude mechanical, thermic, or chemical origins
(21, 22). The nervous system sensitization occurs basically by
neurogenic inflammation, mast cell activation, N-methyl-Daspartate (NMDA) receptors activation, and glial activation
(1, 2), which play an important role in the maintenance and
subsequent pain chronicity in SCD individuals.
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Maladaptive CNS plasticity
mechanisms and ways to evaluate it

After joint tissue injury, the pro-inflammatory mediators
such as bradykinins and prostaglandins interact with receptors
or transient receptor potential vanilloid type 1 (TRPV1)
of nociceptive fibers and sensibilize them to augment their
response to a noxious stimulus (2, 22). Once activated,
the nociceptors release peptides and neurotransmitters such
as calcitonin gene-related peptide and substance P, which
further contribute to the inflammatory response, causing
vasodilation, swelling, and mast cell activation. Mast cells
act by degranulation of histamine, which further sensibilize
nociceptors (23). Interestingly, serum levels of substance P
are increased in SCD individuals during the vaso-occlusive
crisis and baseline state (24) and have been associated with
to use of hydroxyurea (25). This cascade of biochemical
events lowers the activation threshold of true nociceptors
and recruits previously unresponsive silent nociceptors, which
induce hyperalgesia and allodynia in joint pathologies in SCD
individuals (26).
N-methyl-D-aspartate receptors are involved in the longterm potentiation process and are a crucial player in the
chronicity of pain (27). At the spinal cord level, the constant
nociceptive information arrives in the dorsal horn and provoke
the release of glutamate neurotransmitter in presynaptic
terminals that interacts with NMDA receptors post-synaptic
(3). When NMDA receptors are activated, the nitric oxide
is synthesized in the presynaptic terminals, increasing the
expression of voltage-gated Ca2+ channels mainly responsive
to P substance and glutamate (3). Concurrently, glial activation
releases pro-inflammatory cytokines and more glutamate in this
synaptic environment (1, 3). Thus, these series of intracellular
signaling cascades augment and facilitate the transmission of
nociceptive information.
These nociceptive information reaches higher encephalic
areas, such as Rostral Ventromedial Medulla (RVM),
Periaqueductal Gray Matter (PAG), thalamus, amygdala,
anterior cingulate cortex, somatosensory, prefrontal, and
motor cortices (28, 29) that process and modulates the
nociceptive information. However, nociceptive modulation
can occur before reaching the thalamus and other brain
structures (30). Once that nociceptive information reaches
the thalamus, it processes it and redirects it to cortical areas
of the primary and secondary somatosensory cortex through
thalamocortical and thalamus-amygdala connections (29).
The PAG, in turn, receives inputs from these superior centers
and sends them to the RVM medulla, which through axonal
fibers of “on” and “off ” cells, modulate neuronal activity,
facilitating or inhibiting the transit of nociceptive information
in the dorsal horn of the spinal cord both presynaptic
and post-synaptic (30, 31). This complex endogenous
mechanism forms a pain processing and control system,
often presenting a maladaptive function in chronic joint pain
(Figure 1).
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Dysfunction of descending inhibitory
control in CJP
Central nervous system has various ways of inhibiting
the input of pain information to higher processing centers.
Descending inhibitory control is a mechanism of diffuse
pain inhibition. Studies with conditions of CJP similar to
SCD, such as hip and knee osteoarthritis, showed that
the descending inhibitory control dysfunction might be an
important triggering factor for central sensitization and chronic
pain (32). Although some studies have found no consistent
results about dysfunctions of descending inhibitory control in
adult SCD individuals (10, 33), neuroimage data from another
study with adult SCD individuals showed that there is an
increased resting-state functional connectivity between the PAG
and cerebellum in SCD individuals (34) which can affect RVM’s
“on” and “off ” cells activity. In pediatric SCD individuals,
the dysfunctions of the descending inhibitory control are few
explored, but data from non-SCD individuals has shown that
deficient endogenous pain inhibition can stem from painful
experiences during infancy (35, 36). Therefore, these data make
us think that the function of the descending inhibitory control
system in SCD still needs to be better understood and evaluated
in the clinical context.
One of the traditional ways of assessing descending pain
inhibitory system is through the paradigm of Conditioned Pain
Modulation (CPM), previously known as “counter-irritation,”
“pain inhibits pain,” and “heterotopic noxious conditioning
modulation,” and “diffuse noxious inhibitory control”(37).
This phenomenon is activated after a set of intense and/or
noxious stimuli, making it a protective endogenous response to
aggression. The evaluation of descending inhibitory control by
the CPM method should be recommended for SCD individuals
due to the malfunctioning of this mechanism is closely related
to the persistence of joint pain in musculoskeletal conditions
such as osteoarthritis and temporomandibular dysfunction (32,
38, 39) (Figure 2). However, clinicians should be aware that the
long-term pain, and the use of opioid agents can result in a
reduced response of CPM scores (40).
In CPM assessment, a pressure threshold meter for applying
painful mechanical stimulus in the thenar region of the nondominant hand has a good coefficient of intra-session reliability
(ICC >0.75). It seems to be a reliable method for performing a
Painful Stimulus Test (PST). The pain caused by the mechanical
stimulus must be of moderate intensity (41, 42). In turn, the
Painful Conditioning Stimulus Test (PCST) can be done with
cold or hot water. However, the immersion of the dominant
hand in a water vessel with a temperature of 46.5◦ C has a
good Intraclass Correlation Coefficient (ICC = 0.79) (42) and
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FIGURE 1

Schematic drawing of the peripheral sensitization, processing, and nociceptive modulation in joint pain: After a noxious stimulus in the joint, the
TRP channels in true nociceptors transduce the nociceptive information and lead it to second-order neurons in the spinal cord. In addition,
when there is a joint injury, a massive release of the pronociceptive chemical substances in/by free nerve endings promotes a depolarization
threshold decrease and an increase in ﬁring frequency rate in both true and silent nociceptors and mechanical receptors. The nociceptive
information reaches the CNS, which processes and modulates it through brain networks and the PAG-RVM system. Speciﬁcally, in SCD patients,
there is increased functional connectivity in areas such as PFC, ACC, M1, SI, and SII cortices. Abbreviations: ACC, anterior cingulate cortex; Amy,
amygdala; CGRP, calcitonin gene-related peptide; Ins, insula; M1, primary motor cortex; PAG, periaqueductal gray matter; PFC, prefrontal
cortex; RVM, rostral ventromedial medulla; SI, primary somatosensory cortex; SII, secondary somatosensory cortex; Tha, thalamus; TRP,
transient receptor potential.
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FIGURE 2

Schematic drawing of the conditioned pain modulation assessment: CPM can be assessed in three steps in the clinical setting. (1) A PST is made
in the non-dominant side of the body (usually the thenar eminence). (2) After a sufficient period so that the pain caused by the PST has ceased, a
PCST is made in a heterotopic region distant from the initially stimulated region and preferably on the contralateral side of the body, lasting 1
minute. (3) The PST is again applied immediately after or concomitantly to a PCST. Abbreviations: CPM, conditioned pain modulation; PST,
painful stimulus test; PCST, painful conditioning stimulus test.

sensitization. However, this term was not part of recognized
by the IASP. Following the proposition of a research group
(43), an IASP force task recently added a new pain term called
“nociplastic pain” into the list of taxonomic definitions for pain
(44), even though it caused a comprehensive discussion related
to its real need and the best way for it to be defined (45–47). This
new term proposes to differentiate the “pain that arises from
altered nociception, despite there is no clear evidence of actual
or threatened tissue damage that causes peripheral nociceptor
activation or evidence of disease or injury to the somatosensory
system that causes pain” from those kinds of pains typically
classified only as nociceptive or neuropathic.
The central sensitization mechanisms involve the
perpetuation of joint pain that can be favored by poor
descending inhibitory control, which over time causes
phenotypic alteration of Aβ fibers specialized in conducting
non-painful stimuli (30). In addition, nociceptive information
is not properly inhibited in the dorsal horn of the spinal cord
and advances freely until it reaches higher areas of the nervous
system, causing a central sensitization of multiple structures
(48). Central sensitization of multiple structures involves a
maladaptive change of important anatomic/functional networks
that process information in all pain dimensions, i.e., sensory,

is more recommended in the SCD context because it can
avoid a vaso-occlusive crisis during the evaluation. Using a
thermometer to verify the heat dissipation and ensure the ideal
temperature during immersion and using the same kilogramsforce generated by the pressure threshold meter during the PST
before and after the PCST may decrease potential measurement
biases (41, 42).
The quantification of the CPM can be made according to the
following equation:

CPM = piPST1 − piPST2
Where piPST1 corresponds to the pain intensity caused by the
first painful stimulus test and piPST2 pain intensity caused by
a second painful stimulus test. A positive result indicates the
presence of a preserved descending inhibitory control, while a
negative result indicates the opposite (42).

Central sensitization in CJP
Previously, the term “centralized pain” was often used
to classify the pain experienced by patients with central
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The sensitization of the pain connectome may be associated
with multiple musculoskeletal and non-musculoskeletal
symptoms found in individuals with severe chronic pain. These
include decreased pain threshold, expansion of pain receptive
field to further regions unrelated to pain, interpretation of
non-painful stimuli as painful, photophobia, bowel diseases,
and sleep, attention, and mood-altering (54, 55). The emergence
of these phenomena may trigger the change of the clinical status
from a musculoskeletal disease to a multi-systems disease.
Typically, those symptoms are under-evaluated by clinicians
and are not related to the presence of persistent pain. However,
these aspects are essential as they help in decision-making and
prediction of patient outcomes, as evidenced by a study that
showed that individuals with central sensitization due to chronic
pain secondary to osteoarthritis of the knee are five times more
likely to have pain refractory to surgical treatment of total knee
arthroplasty (56). In SCD individuals, central sensitization
has been associated with increased vaso-occlusive crises, poor
sleep quality, and psychosocial disorders (10). For this reason,
this should be considered during the evaluation since this is
probably one of the main causes of refractory joint pain (57).
Sensitivity hyperphenomena, such as allodynia or
hyperalgesia to thermic and vibratory stimuli, and mechanical
and thermal temporal summation, have been associated with
central sensitization in non-SCD individuals with chronic pain
(57). These sensitivity deficits are also found in pediatric SCD
individuals, among lower mechanic pain, cold pain, heat pain,
thermal detection thresholds, and heat pain tolerance (58). In
addition, studies with adult SCD individuals showed that they
also present sensory alterations expressed by a higher intensity
of cold pain, heat pain, thermal temporal summation, and
mechanic pain is found in compared with healthy controls
(33, 59).
Some methods are essential in evaluating central
sensitization/nociplastic pain characteristics in clinical and
research settings because they can help evaluate whether CJP
in SCD is influenced and/or supported by central sensitization.
The central sensitization inventory (CSI) is an evaluation
instrument that, although non-specific to SCD, is highly
recommended to be used in clinical practice in the SCD context
(54). The CSI is divided into two parts, A and B. In part A,
25 descriptive alternatives of multidimensional symptoms are
associated with central sensitization. Each alternative has a score
varying from zero (never) to four (always), with a maximum
total score of 100 points. In part B, 10 alternative clinical
conditions are recognized as central sensitivity syndromes (CSS)
(60). The cut-off at 40 points has excellent levels of sensitivity
(81%), specificity (75%), positive predictive (2.93), and negative
predictive value (0.52) to recognize central sensitization (60).
However, despite these good diagnostic accuracy values, the
CSI still needs to be validated in SCD individuals, and its
results should be interpreted with caution. Due to the need for
severity ratings of central sensitization, a 10-point classification

emotional, and cognitive (49). Due to the important role in pain
processing, these anatomic/functional networks are called the
pain connectome (49).
In conditions of chronic non-SCD pain, the default mode
network (DMN), the salience network (SLN), the sensorimotor
network (SMN), and the antinociceptive system are connectome
strongly affected by central sensitization (49, 50). The DMN
includes the medial prefrontal cortex, posterior cingulate cortex,
precuneus, and lateral parietal cortices and is activated in a
resting state of the mind when the individual is instructed not
to think about anything specific (49). Next, SLN comprises
the bilateral insula cortices, anterior cingulate cortex, and
middle cingulate cortex and is activated by salient stimuli that
stand out from the environment (e.g., nociceptive stimulation
caused by the movement of an inflamed joint) (51). The
SMN includes bilateral primary and secondary somatosensory
cortices, primary motor (M1) cortex, and the supplementary
motor area (SMA) and is involved in the descriptive sensory
processing of pain (51). Finally, the antinociceptive system
comprises the PAG and RVM, which, as previously discussed,
are core structures involved in pain modulation (49). This
pain connectome is dynamic due to the capacity to generate
connections within and between themselves (49).
In SCD individuals with chronic pain, some studies
using functional Magnetic Resonance Image (fMRI) alone
or coupled with Electroencephalography (EEG) have found
a maladaptive change in the pain connectome (34, 51–
53). Their results showed that SCD individuals with high
levels of pain and hospitalizations had an increased restingstate functional connectivity between SLN, DMN, and SMN
structures (e.g., dorsal anterior cingulate cortex and the
right precuneus, secondary somatosensory cortex, and the left
precuneus, inferior parietal lobule and the middle cingulate
cortex, right posterior cingulate cortex and the right primary
somatosensory cortex) when compared with individuals with
low levels of pain and hospitalizations (52). SCD individuals
also presented hypoconnectivity of SMN structures (i.e., motor
cortex) compared to healthy controls and between other regions
outside of the SMN, such as the dorsolateral prefrontal and
parietal cortices (51). In addition, this same study found that
SCD increased functional connectivity between DMN and
SLN structures (e.g., precuneus/ posterior cingulate cortex
and temporal regions) (51). Finally, studies comparing SCD
individuals and healthy controls found changes in functional
connectivity of the PAG (a core structure of the antinociceptive
system) (34, 53). Functional connectivity between the PAG
and the anterior cingulate cortex (a structured core of SLN)
is decreased in SCD patients when compared to healthy
individuals but increased between the PAG and several cortical
regions that play functions of sensory processing, motor
processing/executive function, emotion and memory/learning
when SCD patients were compared with those without
pain (53).

Frontiers in Medicine

06

frontiersin.org

Lopes et al.

10.3389/fmed.2022.679053

The safety of the QST protocol in the clinical setting
has been previously tested in subjects with SCD, and
there was no perpetuation or worsening of pain after its
application (8). However, attention is necessary because data
show that after QST testing in SCD patients, there are
changes in pro-inflammatory biomarkers such as increased
levels of Interleukin 6 (IL-6), substance P, and tumor
necrosis Factor-alpha (TNFα) (33). In SCD, the thermal
pain threshold (TPT) to cold <17.01◦ C and heat <43.91◦ C
are indicative of impaired nerve sensitivity, and pressure
pain threshold (PPT) <4.42 g is indicative of the existence
of altered sensory function (68). Thermal pain threshold
(TPT) assessment with temperature in 32◦ C baselines and
an increasing/decreasing temperature at a rate of 1.5◦ C/s is
used in clinical settings (ICC >0.55) (69). In cases of nonSCD pain, specifically osteoarthritis of the knee, the PPT
increasing pressure at a rate of 0.5 kgf/s has a good diagnostic
reliability value varying according to the evaluated joint site
(ICC: 0.64–0.73) (70).
Finally, another way of assessing central sensitization in
individuals with SCD uses its typical clinical criteria checklist
(71) developed by a consensus of experts. Although this
checklist is non-specific to SCD individuals, it is also useful for
clinicians and healthcare professionals because it helps identify
signs and symptoms characteristic of central sensitization,
such as pain disproportionate to injury, disproportionate
aggravating/easing factors, and psychosocial symptoms, and
diffuse palpation. These discriminative items indicate the
presence of central pain sensitization with excellent accuracy
values (sensitivity 91.8%, specificity 97.7%, positive predictive
value 91.8, and negative predictive value 97.7) (72). Thus, using
these instruments during the evaluation of SCD individuals
with CJP may help in the more precise knowledge of
the mechanism underlying the patient’s pain. This clinical
criteria checklist provides a basis for better clinical decisionmaking and possibly less chance of non-adherence to the
proposed treatment.

with severity intervals was created, consisting of the following
categories: subclinical (≤29), mild (30–39), moderate (40–49),
severe (50–59) and extreme (≥60) (61). This severity rating
allows better utilization of CSI in clinical practice and may help
as a parameter of the therapeutic response. This instrument has
been culturally translated and validated in several languages
(62, 63).
Quantitative sensory tests (QST) are another way to
assess central sensitization (10, 57, 64). All systematic sensory
evaluations that allow quantified responses can be viewed as
a QST. However, a set of QST (mechanical, thermal, and
vibratory) was standardized to evaluate the integrity of the
somatosensory system and to guarantee the accuracy and
reproducibility of the findings (65). QST protocols consider
several sensory parameters, as well as biological aspects ranging
from body temperature to trophic changes in the musculature
(64, 65). However, although QST protocols can be performed in
both bedridden and non-bedridden individuals, their complete
execution is time-consuming and can be impracticable in some
clinical contexts. In this context, there are some attempts
to validate a bedside QST as a low-cost and time-efficient
alternative (66, 67).
The bedside QST can be easily applied in clinical routine,
and its execution does not require a large training time.
Studies showed that bedside QST protocol using low-cost
equipment could be used in each step of the sensory assessment
procedure, such as (a) 3 cm² metal coin/piece with 22◦ C or
37◦ C (cold/warm detection thresholds); (b) cotton wool/Q-tip
(mechanical detection threshold); (c) tuning fork (vibration
detection threshold); (d) 10-ml syringe sealed or toothpick
(mechanical and pressure pain threshold); (e) glass vial filled
with hot water 40◦ C or metal pieces with 45◦ C (heat pain
threshold); (f) ice cubes in a plastic bag or metal piece with
8◦ C (cold pain threshold); (g) toothpick (temporal summation)
(66, 67). However, the correlation between bedside QST and
standard QST protocol is variable and impacted by the expertise
of a healthcare professional.
A study proposed three steps of a decision tree that
helps clinicians to interpret the findings of QST evaluation of
mechanical detection threshold (Aβ fibers), cold pain (Aδ fibers),
and heat pain (C fibers), specifically in SCD individuals (8). In
the clinical setting, QST stimuli should be evaluated in both
painful and non-painful sites. In the first step, if all QST findings
are negative, the clinical interpretation must be that there is
no central or peripheral sensitization. In the second step, if
mechanical stimuli findings in the non-painful site are positive,
then the clinical interpretation must be that there is central
sensitization. In the third step, if cold or heat pain is present in
the painful site and these same painful stimuli result negative
in the non-painful site, then the clinical interpretation must be
that there is peripheral sensitization. Finally, the decision tree
proposes that if all three steps result in negative findings, then
the interpretation must be that there is mixed pain (8).

Frontiers in Medicine

Motor control modiﬁcations and cortical
reorganization in CJP
In the face of pain, the neuromusculoskeletal system
undergoes adaptive motor modifications that affect motor
control and joint mechanics. These modifications have been
studied over time due to the importance of their understanding
for both clinicians and researchers. Therefore, one theoretical
model (73) was established to clarify the interaction between
pain and motor control changes making the following
propositions: Firstly, the adaptation of the motor control to pain
is a consequence of the redistribution of the activity within and
between muscles. Secondly, the change in mechanical behavior
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initially has a protective function of preventing further pain or
injury. However, in the long term, it involves changes in various
levels of the nervous system, which lead to increased joint load,
decreased mobility, and variability of movement and muscle
weakness (73).
In the presence of CJP, motor and sensory primary cortical
reorganization are associated with motor control impairment.
This cortical reorganization has been demonstrated in
non-SCD adult individuals with low back pain (74, 75),
chronic lateral epicondylalgia (76), osteoarthritis of
the knee (77), and chronic patellofemoral pain (78),
but there is no study with pediatric individuals. This
cortical reorganization is expressed through the overlap
(i.e., blurring) or retraction in the areas of somatotopic
representation of the motor homunculus. The greater the
cortical reorganization, the greater the perpetuation of the
pain (77).

The intracortical inhibitory system, modulated by tonic
GABAergic activity, plays an important role in the development
of cortical somatotopic representations. This specific function
is due to mechanisms that differentiate cortical efferent motor
actions, either by facilitating muscle activation during a
motor task or by inhibiting undesirable muscular activations
(79). Although changes in intracortical inhibition are not a
consensus (80), intracortical inhibitory dysfunction mediated by
GABAergic connections has been demonstrated in individuals
with chronic pain (81) through Transcranial Magnetic
Stimulation (TMS), a technique that has been often used to
assess cortical connectivity.
Transcranial magnetic stimulation also allows the evaluation
of muscles’ cortical representations through cortical mapping.
Briefly, cortical mapping through TMS is made using a set
of pulses with intensity fixed in accord with a percentage
of the maximal stimulator output (82). This set of pulses

FIGURE 3

Schematic drawing of the measures of motor cortical excitability with tms and mapping of motor cortical representation in joint pain condition:
Using TMS, Motor Cortical Excitability can be expressed by corticospinal (MEP) and intracortical measures (ICF, IIC, and }CSP). In the CJP, the
CSP, SICI, and MEP are decreased, and the SICF is increased compared to the healthy condition. The Standard Motor Cortical Representation in
the presence of pain can classically be changed into two possible basic forms. (1) An Overlapping of the Motor Cortical Representation adjacent
to that affected by pain; (2) A Retraction of the Motor Cortical Representation affected by pain and an increase in the adjacent representation.
}CSP is obtained only when the assessment is made during a muscle contraction. Abbreviations: CSP, cortical silent period; SICF, short-interval
intracortical facilitation; SICI, short-interval intracortical inhibition; MEP, motor evoked potential; TMS, transcranial magnetic stimulation.
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should be applied at various scalp sites using a figure-ofeight coil and a spatial coordinate system referenced to the
vertex (83), and the amplitude of MEPs evoked in contralateral
muscles is measured (82). However, although the assessment
of cortical mapping through TMS can be useful in clinical
settings, there are no studies evaluating its diagnostic reliability
(Figure 3).
In SCD individuals, CJP is possibly associated with
maladaptive motor behavior and cortical representation changes
due to their chronic and disabling pain (7). The changes
in functional connectivity of the structures are involved in
the descending inhibitory control of nociceptive information
in individuals with SCD (34) and can be associated with
intracortical inhibition (84). Thus, although TMS evaluation
is not specific to SCD individuals, clinicians and healthcare
professionals should be used to investigate these possible
cortical alterations both in adult and pediatric SCD individuals
with CJP.

It is common that after joint injuries, there is the presence
of weakness in the adjacent involved musculature. The possible
cause for this muscle weakness is the presence of a central
reflex inhibition that can provoke a failure to fully recruit the
motor units and/or a suboptimal firing of the motor units that
are recruited (85), preventing the complete activation of the
surrounding musculature to the injured joint during a maximal
voluntary muscular contraction. This phenomenon has been
called Arthrogenic Muscle Inhibition (AMI) (86).
Arthrogenic muscle inhibition can be interpreted as
a mechanism of physiological protection to prevent new
lesions and potentiation of tissue repair (87). However,
AMI may persist for several months or even years
after injury (88). This persistence may compromise the
rehabilitation process by negatively impacting strengthening
protocols, thus, contributing to injury progression and

FIGURE 4

Schematic drawing of the arthrogenic muscle inhibition evaluation by central activation rate and interpolated twitch technique: Although the
knee joint is the most evaluated with the CAR and the ITT methods, their methodological simplicity allows the assessment of AMI to be also
used in other joints (e.g., the hip joint in the ﬁgure above). The quantiﬁcation of the evaluation can be done using speciﬁc mathematical
formulas for each method. a. stimulus-evoked torque at rest; b. voluntary torque at the time of stimulus delivery; c, peak torque evoked due to
the electrical pulse. Abbreviations: AMI, arthrogenic muscle inhibition; CAR, central activation rate; ITT, interpolated twitch technique.
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TABLE 1 Summary of the main central nervous system maladaptive changes, assessment methods, clinical interpretation, and diagnostic reliability
that can be used in CJP related to sickle cell disease.

CNS maladaptive changes
in chronic joint pain

Assessment methods
or instruments

Clinical interpretation

Diagnostic reliability

Insufficiency of descending

• Conditioned pain

• piPST1 > piPST2 = Descending inhibitory

• PST:

inhibitory control

modulation (42)

control is functioning
• piPST1 < piPST2 = Descending inhibitory
control system is faulty

Central sensitization

• Central sensitization

• Severity ratings:

inventory (60,61)

Pressure

threshold

meter

(ICC >0.75)
• PCST: Hot water in 46.5◦ C
(ICC = 0.79)
• Cut-off at 40 points:

Subclinical (≤29)

Sensitivity (81%)

Mild (30-39)

Specificity (75%)

Moderate (40-49)

Positive predictive value (2.93)

Severe (50-59)

Negative predictive value (0.52)

Extreme (≥60)
• Quantitative sensory test
(68-70)

• TPT to cold <17.01◦ C and heat <43.91◦ C
are indicative of impaired nerve sensitivity
• PPT <4.42 g is indicative of the existence
of an altered sensory function

• TPT:

32◦ C

baselines

decreased/increased

with

temperature

at a rate of 1.5◦ C/s (ICC >0.55)
• PPT: Increasing pressure at a rate of
0.5 kgf/s (ICC: 0.64–0.73)

• Clinical criteria checklist
(71,72)

Modifications of motor control and
cortical reorganization

Arthrogenic muscle inhibition

• Cortical mapping by

• Pain disproportionate to injury

Specificity (97.7%)

factors; psychosocial symptoms; diffuse

Positive predictive value (91.9) Negative

palpation

predictive value (97.7)

• There is an overlap (blurring) or retraction

transcranial magnetic

in the areas of somatotopic representation

stimulation (77)

of the motor cortex

• Central activation rate
(91,96)

Sensitivity (91.8%)

disproportionate aggravating/easing

• When the central activation rate is below

• CAR: Within- measurement

95%, it is an indication that there are

(ICC = 0.94) Between-measurement

muscle fibers that are not being activated

(ICC = 0.86)

by central neural pathways
• Interpolated Twitch
Technique (85,87)

• The higher the proportion, the greater the
number of muscle fibers that are not

• ITT: Within measurement
(ICC = 0.89)

centrally activated
Abbreviations: CAR, Central Activation Rate; ITT, Interpolated Twitch Technique; ICC, Intraclass Correlation Coefficient; PCST, Painful Conditioning Stimulus Test; piPST1, pain
intensity of first Painful Stimulus Test; piPST2, pain intensity of second Painful Stimulus Test; PST, Painful Stimulus Test; TPT, Thermal Pain Threshold; PPT, Pressure Pain Threshold.

associated dysfunction (87). Common conditions such
as joint pain, ligamentous laxity, and joint effusion are
potential factors that facilitate the establishment of AMI
(86).
In the AMI, there is an alteration of the firing of the
joint receptors that send signals for the medullary inhibitory
interneurons, causing inhibition of the activity of the alpha
motoneurons and, consequently, the musculature involved in
the affected joint (87). Joint pain may contribute to the AMI due
to the alteration of the excitability of the flexor reflex pathway
(86), which has the characteristic of facilitating the flexor and
inhibiting the extensor muscles in the region surrounding the
painful joint (89). In addition, joint pain in the knee has been
associated with decreased muscle activation of the quadriceps
(90, 91).

Frontiers in Medicine

Although a systematic review has shown that the
mechanisms of AMI are mostly studied in knee joint injuries
(91), it may also be observed in individuals with pathologies
in the hip. In this condition, AMI may be represented by
a decrease in Gluteus maximus activation during extension
activity in pronation (92). In this sense, as the most affected
joint in SCD is the hip due to avascular osteonecrosis (7), the
healthcare professional must be aware of the possibility of
AMI playing an important role in this condition. However,
many SCD individuals are likely quite physically deconditioned
due to limited physical activity because of fatigue (93) or
concerns about triggering vaso-occlusive crises after physical
activity (94). This clinical characteristic in SCD individuals
can make AMI assessment challenging because of the potential
confounding biases related to physical deconditioning or
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changes may be assessed by a set of tests and/or questionnaires
that are already available and could be useful in the clinical
assessment and research in SCD. In the clinical setting,
every healthcare professional can measure these maladaptive
changes through instruments and methods with good diagnostic
reliability (Table 1). These maladaptive plasticity changes may
contribute to persistent pain in SCD, but there is a substantial
lack of evidence regarding this aspect. However, future studies
should be performed to elucidate and confirm these possible
maladaptive changes in the nervous system in SCD individuals
related to CJP to understand and treat the pain in those patients
with better results.

structural musculoskeletal alterations, especially in bilateral
affections. On the other hand, in unilateral affections, these
confounding biases can be minimized by comparison with
the unaffected side. To date, no studies have evaluated AMI
mechanisms in both adults and pediatric SCD individuals, and
in future studies, the impact of physical deconditioning on AMI
assessment should be better clarified.
In the clinical setting, AMI can be assessed using two
quantitative methods: the Central Activation Rate (CAR) and
the Interpolated Twitch Technique (ITT) (85, 91, 95). In both
methods, the individual is asked to make a maximal voluntary
isometric contraction (MVIC), and the force/torque generated
by the muscle is registered. Then, when the force/torque plateau
is reached, a maximal or supramaximal electrical stimulus
is introduced. However, in the ITT method, this electrical
stimulus can also be made initially with the muscle at rest
(85, 91, 95). For electrical stimulus, 10 pulses, 100 Hz,200 µs
pulse duration, and 400 V appear to be a reliable stimulation
parameters for muscle contraction (85). Individuals with CAR
>95% have a muscle fully activated by voluntary central
stimulation, and those with less than that have some central
muscle inactivation (91). In the ITT method, the higher the
index score, the greater the number of fibers that are not
centrally activated (85). Both methods seem simple, easily
performed, and therefore feasible in clinical practice and
research (Figure 4).
When comparing CAR and ITT in the capacity to estimate
the quadriceps muscle activation, there was a significant
variation between methods, with an estimated difference of up
to 5.5% (85). In addition, it is suggested that ITT is a more
accurate measure since the CAR might overestimate voluntary
muscle activation (85). Some articles have assessed and reported
good reliability of these methods in knee joints (96, 97), and
the CAR method was found reliable within- (ICC = 0.94)
and between-measurement sessions (ICC = 0.86) (96) while in
the ITT method the reliability within measures was (ICC =
0.89) (97). Unfortunately, no studies evaluated the diagnostic
value of these methods in joints frequently affected by SCD
individuals, such as the hip, shoulder, and elbow. Although
both CAR and ITT are not specific to SCD individuals, these
methods should be used in clinical practice to evaluate CJP in
SCD individuals.
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